Status:
COMPLETED
A Study to Evaluate the Bioavailability of BMS-986205
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Assess the absolute bioavailability of a tablet formulation of BMS-986205 following simultaneous oral administration of BMS-986205 and intravenous infusion of \[13C\]BMS-986205 solution for intravenou...
Eligibility Criteria
Inclusion
- Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive
- Must have normal renal function demonstrated by an estimated glomerular filtration rate, calculated by Chronic Kidney Disease Epidemiology Collaboration formula
- Women must not be of childbearing potential (cannot become pregnant)
Exclusion
- Women who are of childbearing potential or breastfeeding
- Any significant acute or chronic medical illness
- Active tuberculosis (TB) requiring treatment or documented latent TB at screening
- Other protocol defined inclusion / exclusion criteria could apply
Key Trial Info
Start Date :
January 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 16 2018
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03374228
Start Date
January 4 2018
End Date
February 16 2018
Last Update
June 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Clinical
Nottingham, Ruddington Fields, United Kingdom, NG11 6JS